Dallas, TX: ReportsandReports announce it will carry Astellas Pharma Inc.: PharmaVitae Profile Market Research Report in its Store.
Browse complete Astellas Pharma Inc.: PharmaVitae Profile Report
This analysis examines the historical and forecast performance for Astellas in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Astellas’s performance against key rivals in the prescription pharmaceutical sector
- Determine the long-term outlook of Astellas’s diverse prescription pharmaceutical portfolio
- Evaluate the unique corporate strategies being pursued by Astellas in its domestic Japanese market and in the US
Table of Content
CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 7
Astellas: PharmaVitae forecasts at a glance 8
Strategic insight 9
M&A helps reinforce focus on Rx pharmaceuticals 9
Cost containment and share buybacks drive investor returns post-merger 11
Flagship organ rejection franchise likely to exhibit strong defense against generic compeition 13
Lifecycle management and generic insulation vital in sustaining medium-term organ rejection revenues 13
Long-term focus on organ rejection underscored by continuing pipeline efforts 15
SWOT analysis 17
Strengths 17
Weaknesses 20
Opportunities 21
Threats 22
CHAPTER 3 QUARTERLY NEWS UPDATE 26
Product developments 26
Deals and alliances 28
Product deals 28
Technology deals 28
Company announcements 29
Future product milestones 29
CHAPTER 4 COMPANY INTRODUCTION 30
Key findings 30
Background 31
Key corporate developments 31
M&A history 34
Merger of Yamanouchi and Fujisawa 34
Acquisiiton of Agensys 35
Current corporate structure 36
Prescription (Rx) pharmaceuticals 36
Other 36
CHAPTER 5 COMPANY SALES 37
Key findings 37
Prescription pharmaceutical sales and growth rate analysis, 2001-13 38
Historical analysis 39
Forecast analysis 40
Product analysis 41
Product analysis, 2001-07 42
Growth drivers 43
Growth resistors 44
Product analysis, 2007-13 45
Growth drivers 46
Growth resistors 48
Therapy area analysis 49
Therapy area analysis, 2001-07 50
Therapy area analysis, 2007-13 51
Therapy area focus, 2001-13 52
Geographic analysis 53
Geographic analysis, 2001-07 54
Geographic analysis, 2007-13 56
Geographic focus, 2001-13 58
Launch/core/expiry analysis 59
Explanation of launch/core/expiry analysis 59
Launch analysis, 2007-13 60
Core analysis, 2007-13 61
Expiry analysis, 2007-13 62
Launch/core/expiry configuration, 2007-13 63
Molecule type analysis 64
Molecule type analysis, 2001-07 65
Molecule type analysis, 2007-13 65
Externalization analysis 66
Externalization analysis, 2001-07 67
Externalization analysis, 2007-13 69
CHAPTER 6 COMPANY FINANCIALS 71
Key findings 71
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 73
Financial statements, 2001-07 74
Profit and loss account, 2001-07 74
Balance sheet, 2001-07 75
Operating costs and profit analysis 77
Operating costs and profit analysis, 2001-07 78
Operating cost ratio and profit margin analysis, 2001-07 79
Operating cost ratio and profit margin analysis, 2007-13 80
Operating costs and profit analysis, 2007-13 82
Return on capital employed analysis 83
Capital employed analysis, 2001-07 84
Return on capital employed (RoCE) analysis, 2001-07 86
Market capitalization analysis 89
Market capitalization analysis, 2001-07 89
Total shareholder returns analysis, 2001-07 90
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 92
Key findings 92
Overview 93
Cardiovascular 94
Micardis 94
Overview 95
Sales forecast 97
Lipitor 100
Overview 101
Sales forecast 102
Kynapid 104
Overview 105
Sales forecast 106
Immunology and inflammation 109
Prograf/Advagraf 109
Overview 110
Sales forecast 112
Urology and gender-specific health 116
Vesicare 116
Overview 117
Sales forecast 118
Harnal 121
Overview 122
Sales forecast 123
Infectious diseases 125
Arbelic 125
Overview 126
Sales forecast 127
CHAPTER 8 APPENDIX 131
R&D pipeline 131
References 132
Abbreviations 133
Exchange rates 134
Browse complete Astellas Pharma Inc.: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Astellas Pharma Inc.-Company Report
Astellas Pharma Inc. – SWOT Analysis
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
